Siemens forms molecular imaging division:
This article was originally published in Clinica
Executive Summary
Following its $1bn acquisition of CTI Molecular Imaging, Siemens has formed a new division called Siemens Medical Solutions Molecular Imaging. The business combines CTI's PET activities with Siemens' nuclear medicine business. It will be led by Michael Reitermann, hitherto president of Siemens Nuclear Medicine, while its chief scientific advisor will be by Dr Ronald Nutt, founder and former president and CEO of CTI Molecular Imaging.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.